Search Result
Results for "
antiplatelet aggregation
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-15799
-
|
P2Y Receptor
|
Cardiovascular Disease
|
AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .
|
-
-
- HY-N2081
-
|
Others
|
Inflammation/Immunology
Cancer
|
Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .
|
-
-
- HY-B0428A
-
OKY-046 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel sodium is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
-
- HY-146498
-
|
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
Antiplatelet agent 1 (compound 7q) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 1 can be used for researching platelet aggregation .
|
-
-
- HY-146499
-
|
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
Antiplatelet agent 2 (compound 7p) is a Ticagrelor analoguehas, possessing antiplatelet activity. Antiplatelet agent 2 can be used for researching platelet aggregation .
|
-
-
- HY-N7991
-
-
-
- HY-N3048
-
|
Others
|
Cardiovascular Disease
|
Piperlotine D is an antiplatelet aggregation agent. Piperlotine D can be extracted from Piper lolot with antiplatelet aggregation activity. Piperlotine D inhibits arachidonic acid-induced platelet aggregation with an IC50 of 43.4 μg/mL .
|
-
-
- HY-125123
-
|
Others
|
Cardiovascular Disease
|
Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis .
|
-
-
- HY-111755
-
|
P2Y Receptor
|
Cardiovascular Disease
|
Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
|
-
-
- HY-N4228
-
|
Platelet-activating Factor Receptor (PAFR)
|
Cancer
|
6-Methoxydihydroavicine is an alkaloid isolated from Zanthoxylum integrifoliolum. 6-Methoxydihydroavicine has antiplatelet activities and inhibits AA-, collagen- and PAF-induced platelet aggregation in vitro .
|
-
-
- HY-B0428
-
Ozagrel
1 Publications Verification
OKY-046
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM .
|
-
-
- HY-N2081R
-
|
Others
|
Inflammation/Immunology
Cancer
|
Skimmianine (Standard) is the analytical standard of Skimmianine. This product is intended for research and analytical applications. Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .
|
-
-
- HY-N11920
-
-
-
- HY-19638A
-
AR-C69931MX tetrasodium
|
P2Y Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .
|
-
-
- HY-17459
-
(S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation .Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
-
- HY-N0293
-
Peoniflorin
|
HSP
|
Infection
Neurological Disease
Cancer
|
Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .
|
-
-
- HY-119145
-
|
P2Y Receptor
|
Cardiovascular Disease
|
MRS2496 is a selective P2Y1 receptor antagonist with an IC50 value of 1.5 μM, exhibiting antiplatelet aggregation activity. MRS2496 can be used in the research of antiplatelet aggregation and blood-related diseases .
|
-
-
- HY-N0293R
-
|
HSP
|
Infection
Neurological Disease
Cancer
|
Paeoniflorin (Standard) is the analytical standard of Paeoniflorin. This product is intended for research and analytical applications. Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .
|
-
-
- HY-33351
-
-
-
- HY-N3051
-
-
-
- HY-N3047
-
O-Methylpiperolactam B; Piperolactam B methyl ether
|
Others
|
Cardiovascular Disease
|
Piperolactam C (O-Methylpiperolactam B) is a natural alkaloid with anti-platelet aggregation effects .
|
-
-
- HY-N1861
-
Quercetin 3-O-methyl ether peracetate
|
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
3-O-Methylquercetin tetraacetate is an antiplatelet agent. 3-O-Methylquercetin tetraacetate has potent antiplatelet effect on arachidonic acid, collagen-induced and PAF-induced platelet aggregation .
|
-
-
- HY-167743
-
|
Others
|
Cardiovascular Disease
|
Platelet aggregation-IN-2 is an anti-platelet aggregation agent with significant anticoagulant activity. Platelet aggregation-IN-2 can inhibit platelet aggregation reaction and reduce the risk of thrombosis. The application of Platelet aggregation-IN-2 can potentially be used for the prevention and suppression of cardiovascular diseases .
|
-
-
- HY-N3668
-
Cyclomorusin A; Cyclomulberrochromene
|
Others
|
Cardiovascular Disease
|
Cyclomorusin (Cyclomorusin A; Cyclomulberrochromene) is a prenylflavonoid with antiplatelet activity. Cyclomorusin also inhibits markedly collagen-induced platelet aggregation .
|
-
-
- HY-124365
-
|
Others
|
Infection
Cancer
|
Rhamnetin tetraacetate (compound 4) is a xanthone compound with antiplatelet activity. Rhamnetin tetraacetate inhibited platelet aggregation induced by arachidonic acid .
|
-
-
- HY-N3049
-
|
Others
|
Cardiovascular Disease
|
Piperlotine C is an alkaloid isolated from Piper lolot, with anti-platelet aggregation induced by arachidonic acid, and the IC50 is 26.6 µg/mL .
|
-
-
- HY-123112
-
S792892A
|
Others
|
Cardiovascular Disease
|
Hoe 892 (S792892A) is an orally active prostacyclin derivative with antiplatelet aggregation and vasodilatory activity. Hoe 892 can be used in the study of cardiovascular diseases such as thrombosis .
|
-
-
- HY-N12647
-
|
Others
|
Infection
Inflammation/Immunology
|
cis-Hinkiresinol is a bioactive constituent of Rhizoma anemarrhenae. Rhizoma anemarrhenae is reprted to have anti-pathogenic microorganism, hypoglycemic effects, anti-inflammatory, antipyretic effects and anti-platelet aggregation .
|
-
-
- HY-162375
-
|
Others
|
Cardiovascular Disease
|
AF299 can reduce collagen-related peptide-induced platelet Ca 2+ rises and collagen-induced platelet aggregation. AF299 can be used for research of antiplatelet research .
|
-
-
- HY-U00367
-
-
-
- HY-167848
-
XL-118
|
Others
|
Cardiovascular Disease
|
DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
|
-
-
- HY-162558
-
|
Factor Xa
|
Cardiovascular Disease
|
NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-αIIbβ3 interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation .
|
-
-
- HY-111447
-
|
NADPH Oxidase
Apoptosis
|
Cardiovascular Disease
Cancer
|
VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins .
|
-
-
- HY-163504
-
-
-
- HY-120080
-
|
Others
|
Others
|
UR-2922 is a platelet GPIIb/IIIa antagonist with antiplatelet aggregation and cardiovascular disease inhibition activities. UR-2922 has high affinity for human platelet receptors and has good pharmacokinetic properties, and can be used to inhibit cardiovascular diseases.
|
-
-
- HY-N12067
-
|
Others
|
Inflammation/Immunology
|
Columbianetin β-D-glucopyranoside can be isolated from Angelicae pubescentis radix and has antiplatelet aggregation, anti-inflammatory and analgesic activities. Columbianetin β-D-glucopyranoside exerts significant protective effects against glutamate-induced toxicity .
|
-
-
- HY-124371
-
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects .
|
-
-
- HY-N0120
-
(E/Z)-Piceid
|
Others
|
Inflammation/Immunology
|
(E/Z)-Polydatin ((E/Z)-Piceid) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum. (E/Z)-Polydatin has anti-platelet aggregation, anti-oxidative action of low-density lipoprotein (LDL), cardioprotective activity, anti-inflammatory and immune-regulating functions .
|
-
-
- HY-10119
-
SCH 530348
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
-
- HY-10119A
-
SCH 530348 sulfate
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
-
- HY-19638
-
AR-C69931MX
|
P2Y Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .
|
-
-
- HY-123669A
-
|
P2Y Receptor
|
Cardiovascular Disease
|
Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .
|
-
-
- HY-15284
-
PCR 4099
|
P2Y Receptor
|
Cardiovascular Disease
|
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
-
- HY-15284A
-
PCR 4099 hydrochloride
|
P2Y Receptor
|
Cardiovascular Disease
|
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
-
- HY-15284B
-
PCR 4099 (Maleic acid)
|
P2Y Receptor
|
Cardiovascular Disease
|
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
-
- HY-B0428B
-
OKY-046 hydrochloride
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
|
-
-
- HY-108555
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC50 of 0.29 μM. .
|
-
-
- HY-B0428BR
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Ozagrel (hydrochloride) (Standard) is the analytical standard of Ozagrel (hydrochloride). This product is intended for research and analytical applications. Ozagrel hydrochloride (OKY-046 hydrochloride) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel hydrochloride is an antiplatelet agent, which selectively inhibits human platelet aggregationwith an IC50 of 53.12 μM .
|
-
-
- HY-15284AR
-
|
P2Y Receptor
|
Cardiovascular Disease
|
Prasugrel (hydrochloride) (Standard) is the analytical standard of Prasugrel (hydrochloride). This product is intended for research and analytical applications. Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
-
- HY-128345
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP) .
|
-
- HY-10119R
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
Vorapaxar (Standard) is the analytical standard of Vorapaxar. This product is intended for research and analytical applications. Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
- HY-10119S
-
SCH 530348-d5
|
Protease Activated Receptor (PAR)
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
Vorapaxar-d5 is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
- HY-N2375
-
|
Wnt
β-catenin
p38 MAPK
|
Metabolic Disease
|
L-Quebrachitol is a methoxy analog of inositol isolated from plants, which has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .
|
-
- HY-159895
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
PAR4 antagonist 7 (Compound 20f) is selective PAR4 antagonist (IC50: 1.72 nM). PAR4 antagonist 7 inhibits PAR4 agonist-induced platelet aggregation. PAR4 antagonist 7 has good metabolic stability. PAR4 antagonist 7 does not show a bleeding tendency in mice .
|
-
- HY-78263
-
NSC 170724; 5-(2-Nitrovinyl)benzodioxole
|
Src
Syk
|
Cancer
|
MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively .
|
-
- HY-P99560
-
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
-
- HY-17459S
-
(S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate
|
P2Y Receptor
Cytochrome P450
|
Cardiovascular Disease
|
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation.Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
|
-
- HY-17459R
-
(S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation .Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
- HY-P1956
-
HSA
|
NF-κB
NO Synthase
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
|
-
- HY-N2515
-
|
NF-κB
PI3K
JAK
Apoptosis
|
Inflammation/Immunology
Cancer
|
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
- HY-149454
-
|
P2Y Receptor
|
Cancer
|
P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of P2Y1 and P2Y12 with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC50 of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.
|
-
- HY-N2515R
-
|
NF-κB
PI3K
JAK
Apoptosis
|
Inflammation/Immunology
Cancer
|
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
- HY-P1956A
-
HSA (Cell culture grade, Endotoxin<0.125 EU/mg)
|
NF-κB
NO Synthase
|
Cardiovascular Disease
Inflammation/Immunology
|
Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, iNOS, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-P1956
-
HSA
|
Native Proteins
|
Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
|
-
- HY-P1956A
-
HSA (Cell culture grade, Endotoxin<0.125 EU/mg)
|
Native Proteins
|
Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin (Cell culture grade, Endotoxin<0.125 EU/mg) is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, iNOS, and peroxynitrite (ONOO −) in the vascular wall, contributing to the reduction of blood pressure .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3082
-
|
Peptides
|
Cardiovascular Disease
|
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99560
-
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N2081
-
-
-
- HY-N0293
-
-
-
- HY-33351
-
-
-
- HY-N7991
-
-
-
- HY-N3048
-
-
-
- HY-125123
-
-
-
- HY-N4228
-
-
-
- HY-N2081R
-
-
-
- HY-N11920
-
-
-
- HY-N0293R
-
|
Structural Classification
Other Monoterpenes
Paeonia lactiflora Pall.
Terpenoids
Source classification
Plants
Paeoniaceae
|
HSP
|
Paeoniflorin (Standard) is the analytical standard of Paeoniflorin. This product is intended for research and analytical applications. Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity .
|
-
-
- HY-N3051
-
-
-
- HY-N3047
-
-
-
- HY-N1861
-
-
-
- HY-N3668
-
-
-
- HY-N3049
-
-
-
- HY-N12647
-
-
-
- HY-N12067
-
-
-
- HY-124371
-
|
Structural Classification
Flavonoids
Viburnaceae
Source classification
Plants
Biflavones
Viburnum lantana L.
|
Phosphodiesterase (PDE)
|
Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects .
|
-
-
- HY-N0120
-
-
-
- HY-N2375
-
-
-
- HY-N2515
-
-
-
- HY-N2515R
-
|
Panax ginseng C. A. Meyer
Triterpenes
Structural Classification
Terpenoids
Source classification
Plants
Araliaceae
|
NF-κB
PI3K
JAK
Apoptosis
|
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures .
Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB .
Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis .
Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-10119S
-
|
Vorapaxar-d5 is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner .
|
-
-
- HY-17459S
-
|
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation.Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: